imatinib mesylate has been researched along with Hypertrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, O; Amemiya, S; Baba, A; Fujita, N; Gonoi, W; Hagiwara, A; Kawahara, T; Kurokawa, M; Kurokawa, R; Nakai, Y; Ota, Y; Yamaguchi, H | 1 |
| Akizawa, T; Hirai, Y; Iyoda, M; Kuno, Y; Shibata, T | 1 |
2 other study(ies) available for imatinib mesylate and Hypertrophy
| Article | Year |
|---|---|
Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Hypertrophy; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2021 |
Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease.
Topics: Angiotensin II; Animals; Benzamides; Collagen; Fibroblasts; Hypertrophy; Imatinib Mesylate; Kidney; Kidney Failure, Chronic; Male; Mesangial Cells; Nephrectomy; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome | 2011 |